Compare NEULAND LABS with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NEULAND LABS vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NEULAND LABS SUN PHARMA NEULAND LABS/
SUN PHARMA
 
P/E (TTM) x 57.0 79.4 71.9% View Chart
P/BV x 4.3 3.4 127.4% View Chart
Dividend Yield % 0.1 0.6 13.3%  

Financials

 NEULAND LABS   SUN PHARMA
EQUITY SHARE DATA
    NEULAND LABS
Mar-20
SUN PHARMA
Mar-20
NEULAND LABS/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs754484 155.7%   
Low Rs247315 78.5%   
Sales per share (Unadj.) Rs594.5136.9 434.4%  
Earnings per share (Unadj.) Rs12.617.5 72.4%  
Cash flow per share (Unadj.) Rs37.026.0 142.3%  
Dividends per share (Unadj.) Rs2.004.00 50.0%  
Dividend yield (eoy) %0.41.0 39.9%  
Book value per share (Unadj.) Rs553.4188.7 293.3%  
Shares outstanding (eoy) m12.832,399.26 0.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.82.9 28.8%   
Avg P/E ratio x39.622.9 173.0%  
P/CF ratio (eoy) x13.515.4 88.0%  
Price / Book Value ratio x0.92.1 42.7%  
Dividend payout %15.822.9 69.1%   
Avg Mkt Cap Rs m6,421958,864 0.7%   
No. of employees `0001.317.8 7.2%   
Total wages/salary Rs m1,23663,624 1.9%   
Avg. sales/employee Rs Th5,949.418,490.6 32.2%   
Avg. wages/employee Rs Th963.83,582.6 26.9%   
Avg. net profit/employee Rs Th126.42,357.6 5.4%   
INCOME DATA
Net Sales Rs m7,627328,375 2.3%  
Other income Rs m396,360 0.6%   
Total revenues Rs m7,666334,735 2.3%   
Gross profit Rs m1,01969,898 1.5%  
Depreciation Rs m31320,528 1.5%   
Interest Rs m2163,027 7.1%   
Profit before tax Rs m52952,702 1.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,606 0.0%   
Tax Rs m3678,228 4.5%   
Profit after tax Rs m16241,868 0.4%  
Gross profit margin %13.421.3 62.8%  
Effective tax rate %69.415.6 444.3%   
Net profit margin %2.112.8 16.7%  
BALANCE SHEET DATA
Current assets Rs m5,152316,542 1.6%   
Current liabilities Rs m3,576157,064 2.3%   
Net working cap to sales %20.748.6 42.5%  
Current ratio x1.42.0 71.5%  
Inventory Days Days10588 120.0%  
Debtors Days Days91105 86.8%  
Net fixed assets Rs m3,969243,102 1.6%   
Share capital Rs m1292,399 5.4%   
"Free" reserves Rs m6,971450,245 1.5%   
Net worth Rs m7,100452,645 1.6%   
Long term debt Rs m77420,289 3.8%   
Total assets Rs m12,310682,525 1.8%  
Interest coverage x3.518.4 18.8%   
Debt to equity ratio x0.10 243.1%  
Sales to assets ratio x0.60.5 128.8%   
Return on assets %3.16.6 46.7%  
Return on equity %2.39.2 24.7%  
Return on capital %9.511.2 84.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,18774,219 7.0%   
Fx outflow Rs m1,59327,964 5.7%   
Net fx Rs m3,59446,255 7.8%   
CASH FLOW
From Operations Rs m57365,548 0.9%  
From Investments Rs m-487-25,888 1.9%  
From Financial Activity Rs m-55-57,151 0.1%  
Net Cashflow Rs m33-13,857 -0.2%  

Share Holding

Indian Promoters % 36.3 63.7 56.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 63.7 5.1 1,242.3%  
FIIs % 0.0 23.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 63.7 8.3 767.8%  
Shareholders   12,705 133,026 9.6%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NEULAND LABS With:   ELDER PHARMA  FDC  SHASUN PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  

Compare NEULAND LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views on News

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

More Views on News

Most Popular

A Critical Update on the Market(Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers(Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NEULAND LABS SHARE PRICE


Apr 9, 2021 (Close)

TRACK NEULAND LABS

  • Track your investment in NEULAND LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NEULAND LABS 5-YR ANALYSIS

COMPARE NEULAND LABS WITH

MARKET STATS